Manipulation of Inflammasome: A Promising Approach Towards Immunotherapy of Lung Cancer

References

• Trevor KT, Hersh EM, Brailey J, Balloul JM, Acres B. Transduction of human dendritic cells with a recombinant modified vaccinia Ankara virus encoding MUC1 and IL-2. Cancer Immunol Immunother. 2001;50(8):397–407. doi:10.1007/s002620100214.
   PubMed Web of Science ®Google Scholar
• Cohen S, Kaufman HL. TG-4010 Transgene. Curr Opin Investig Drugs. 2004;5(12):1319–1328.
   PubMedGoogle Scholar
• Saavedra D, Crombet T. CIMAvax-EGF: A new therapeutic vaccine for advanced non-small cell lung cancer patients. Front Immunol. 2017;8:269. doi:10.3389/fimmu.2017.00269.
   PubMed Web of Science ®Google Scholar
• Palmer M, Parker J, Modi S, et al. Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer. Clin Lung Cancer. 2001;3(1):49–57. doi:10.3816/clc.2001.n.018.
   PubMedGoogle Scholar
• Xia W, Wang J, Xu Y, Jiang F, Xu L. L-BLP25 as a peptide vaccine therapy in non-small cell lung cancer: a review. J Thorac Dis. 2014;6(10):1513–1520. doi:10.3978/j.issn.2072-1439.2014.08.17.
   PubMed Web of Science ®Google Scholar
• Peled N, Oton AB, Hirsch FR, Bunn P. MAGE A3 antigen-specific cancer immunotherapeutic. Immunotherapy. 2009;1(1):19–25. doi:10.2217/1750743X.1.1.19.
   PubMed Web of Science ®Google Scholar
• Rijavec E, Biello F, Genova C, et al. Belagenpumatucel-L for the treatment of non-small cell lung cancer. Expert Opin Biol Ther. 2015;15(9):1371–1379. doi:10.1517/14712598.2015.1073709.
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–135. doi:10.1056/NEJMoa1504627.
   PubMed Web of Science ®Google Scholar
• Kazandjian D, Suzman DL, Blumenthal G, et al. FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy. Oncologist. 2016;21(5):634–642. doi:10.1634/theoncologist.2015-0507.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–2465. doi:10.1056/NEJMoa1200694.
   PubMed Web of Science ®Google Scholar
• Lim SH, Sun J-M, Lee S-H, et al. Pembrolizumab for the treatment of non-small cell lung cancer. Expert Opin Biol Ther. 2016;16(3):397–406. doi:10.1517/14712598.2016.1145652.
   PubMed Web of Science ®Google Scholar
• Akamine T, Toyokawa G, Tagawa T, Seto T. Atezolizumab in non-squamous non-small cell lung cancer. J Thorac Dis. 2018;10(Suppl 26):S3155–S3159. doi:10.21037/jtd.2018.07.92.
   PubMedGoogle Scholar
• Antonia S, Goldberg SB, Balmanoukian A, et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: A multicentre, phase 1b study. Lancet Oncol. 2016;17(3):299–308. doi:10.1016/S1470-2045(15)00544-6.
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bondarenko IN, Luft A, et al. Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non-small cell lung cancer (NSCLC). JCO. 2010;28(15_suppl):7531–7531. doi:10.1200/jco.2010.28.15_suppl.7531.
   Google Scholar
• Lee J-H, Chen TW-W, Hsu C-H, et al. A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors. Invest New Drugs. 2020;38(1):99–110. doi:10.1007/s10637-019-00745-z.
   PubMed Web of Science ®Google Scholar
• Five Prime Therapeutics & Bristol-Myers. Study of cabiralizumab in combination with nivolumab in patients with selected advanced cancers. 2019. https://clinicaltrials.gov/show/NCT02526017. Accessed August 24, 2020.
   Google Scholar
• A study of emactuzumab and atezolizumab administered in combination in participants with advanced solid tumors. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02323191. Accessed August 24, 2020.
   Google Scholar
• De Henau O, Rausch M, Winkler D, et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells. Nature. 2016;539(7629):443–447. doi:10.1038/nature20554.
   PubMed Web of Science ®Google Scholar
• Safety Study of SEA-CD40 in Cancer Patients. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02376699. Accessed August 24, 2020.
   Google Scholar
• Study of a combination of GSK1795091 and immunotherapies in subjects with advanced solid tumors.- ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03447314. Accessed August 24, 2020.
   Google Scholar
• A study of intratumoral IMO-2125 in patients with refractory solid tumors. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03052205. Accessed August 24, 2020.
   Google Scholar
• Pembrolizumab +/- SD-101 in hormone-naïve oligometastatic prostate cancer with RT and iADT. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03007732. Accessed August 24, 2020.
   Google Scholar
• Depletion of myeloid derived suppressor cells to enhance anti PD-1 Therapy. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03302247. Accessed August 24, 2020.
   Google Scholar
• Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in advanced solid tumors. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02538432. Accessed August 24, 2020.
   Google Scholar
• Jacobs JFM, Punt CJA, Lesterhuis WJ, et al. Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients. Clin Cancer Res. 2010;16(20):5067–5078. doi:10.1158/1078-0432.CCR-10-1757.
   PubMed Web of Science ®Google Scholar
• Rech AJ, et al. CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients. Sci Transl Med. 2012;4(134):134ra62. doi:10.1126/scitranslmed.3003330.
   PubMed Web of Science ®Google Scholar
• Sugiyama D, Nishikawa H, Maeda Y, et al. Anti-CCR4 mAb selectively depletes effector-Type FoxP3 + CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci USA. 2013;110(44):17945–17950. doi:10.1073/pnas.1316796110.
   PubMed Web of Science ®Google Scholar
• Kurose K, Ohue Y, Wada H, et al. Phase Ia study of FoxP3+ CD4 Treg depletion by infusion of a humanized anti-CCR4 antibody, KW-0761, in cancer patients. Clin Cancer Res. 2015;21(19):4327–4336. doi:10.1158/1078-0432.CCR-15-0357.
   PubMed Web of Science ®Google Scholar
• Infante JR, Hansen AR, Pishvaian MJ, et al. A phase Ib dose escalation study of the OX40 agonist MOXR0916 and the PD-L1 inhibitor atezolizumab in patients with advanced solid tumors. JCO. 2016;34(15_suppl):101–101. doi:10.1200/JCO.2016.34.15_suppl.101.
   Web of Science ®Google Scholar
• Hamid O, Thompson JA, Diab A, et al. First in human (FIH) study of an OX40 agonist monoclonal antibody (mAb) PF-04518600 (PF-8600) in adult patients (pts) with select advanced solid tumors: Preliminary safety and pharmacokinetic (PK)/pharmacodynamic results. JCO. 2016;34(15_suppl):3079–3079. doi:10.1200/JCO.2016.34.15_suppl.3079.
   Web of Science ®Google Scholar
• Beatty GL, O’Dwyer PJ, Clark J, et al. First-in-human phase I study of the oral inhibitor of indoleamine 2,3-dioxygenase-1 epacadostat (INCB024360) in patients with advanced solid malignancies. Clin Cancer Res. 2017;23(13):3269–3276. doi:10.1158/1078-0432.CCR-16-2272.
   PubMed Web of Science ®Google Scholar
• Hamid O, Bauer TM, Spira AI, et al. Safety of epacadostat 100 mg bid plus pembrolizumab 200 mg Q3W in advanced solid tumors: Phase 2 data from ECHO-202/KEYNOTE-037. JCO. 2017;35(15_suppl):3012–3012. doi:10.1200/JCO.2017.35.15_suppl.3012.
   Google Scholar
• Wallin JJ, et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat Commun. 2016;7:12624. doi:10.1038/ncomms12624.
   PubMed Web of Science ®Google Scholar
• Hanks BA, Holtzhausen A, Evans K, Heid M, Blobe GC. Combinatorial TGF-β signaling blockade and anti-CTLA-4 antibody immunotherapy in a murine BRAF V600E -PTEN-/- transgenic model of melanoma. JCO. 2014;32(15_suppl):3011–3011. doi:10.1200/jco.2014.32.15_suppl.3011.
   Web of Science ®Google Scholar
• Moldoveanu B, Otmishi P, Jani P, et al. Inflammatory mechanisms in the lung. J Inflamm Res. 2009;2:1–11.
   PubMedGoogle Scholar
• Balkwill F, Mantovani A. Inflammation and cancer: back to virchow? Lancet. 2001;357(9255):539–545. doi:10.1016/S0140-6736(00)04046-0.
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009;27:519–550. doi:10.1146/annurev.immunol.021908.132612.
   PubMed Web of Science ®Google Scholar
• Kolb R, Liu GH, Janowski AM, Sutterwala FS, Zhang W. Inflammasomes in cancer: a double-edged sword. Protein Cell. 2014;5(1):12–20. doi:10.1007/s13238-013-0001-4.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.013.
   PubMed Web of Science ®Google Scholar
• Chanda C. Role of inflammatory cytokines during lung cancer progression: a review. Res J Pharm Technol. 2018;11(11):5163–5165. doi:10.5958/0974-360X.2018.00943.5.
   Google Scholar
• Karki R, Kanneganti TD. Diverging inflammasome signals in tumorigenesis and potential targeting. Nat Rev Cancer. 2019;19(4):197–214. doi:10.1038/s41568-019-0123-y.
   PubMed Web of Science ®Google Scholar
• Ting JP-Y, Lovering RC, Alnemri ES, et al. The NLR gene family: a standard nomenclature. Immunity. 2008;28(3):285–287. doi:10.1016/j.immuni.2008.02.005.
   PubMed Web of Science ®Google Scholar
• Song N, Li T. Regulation of NLRP3 inflammasome by phosphorylation. Front Immunol. 2018;9:2305. doi:10.3389/fimmu.2018.02305.
   PubMed Web of Science ®Google Scholar
• Garon EB, Chih-Hsin Yang J, Dubinett SM. The role of interleukin 1β in the pathogenesis of lung cancer. JTO Clin Res Reports. 2020;1(1):100001. doi:10.1016/j.jtocrr.2020.100001.
   Google Scholar
• Timperi E, Focaccetti C, Gallerano D, et al. IL-18 receptor marks functional CD8+ T cells in non-small cell lung cancer. Oncoimmunology. 2017;6:e1328337. doi:10.1080/2162402X.2017.1328337.
   PubMed Web of Science ®Google Scholar
• Huang L, Duan S, Shao H, et al. NLRP3 deletion inhibits inflammation-driven mouse lung tumorigenesis induced by benzo(a)pyrene and lipopolysaccharide. Respir Res. 2019;20(1):20. doi:10.1186/s12931-019-0983-4.
   PubMedGoogle Scholar
• Moossavi M, Parsamanesh N, Bahrami A, Atkin SL, SahebkarA. Role of the NLRP3 inflammasome in cancer. Mol Cancer. 2018;17:158. doi:10.1186/s12943-018-0900-3.
   PubMed Web of Science ®Google Scholar
• Wang L, Zhang L-F, Wu J, et al. IL-1β-mediated repression of microRNA-101 is crucial for inflammation-promoted lung tumorigenesis . Cancer Res. 2014;74(17):4720–4730. doi:10.1158/0008-5472.CAN-14-0960.
   PubMed Web of Science ®Google Scholar
• Grant JL, Fishbein MC, Hong L-S, et al. A novel molecular pathway for snail-dependent, SPARC-mediated invasion in non-small cell lung cancer pathogenesis. Cancer Prev Res (Phila). 2014;7(1):150–160. doi:10.1158/1940-6207.CAPR-13-0263.
   PubMed Web of Science ®Google Scholar
• Kase S, Sugio K, Yamazaki K, et al. Expression of E-cadherin and β-catenin in human non-small cell lung cancer and the clinical significance. Clin. Cancer Res. 2000;29(1):196–4796. doi:10.1016/S0169-5002(00)80667-4.
   Google Scholar
• Guo B, Fu S, Zhang J, Liu B, Li Z. Targeting inflammasome/IL-1 pathways for cancer immunotherapy. Sci. Rep. 2016;6:36107. doi:10.1038/srep36107.
   PubMed Web of Science ®Google Scholar
• Wang F, Liu W, Ning J, et al. Simvastatin suppresses proliferation and migration in non-small cell lung cancer via pyroptosis. Int J Biol Sci. 2018;14(4):406–417. doi:10.7150/ijbs.23542.
   PubMed Web of Science ®Google Scholar
• Xia X, Wang X, Cheng Z, et al. The role of pyroptosis in cancer: pro-cancer or pro-“host”? Cell Death Dis. 2019;10(9):650. doi:10.1038/s41419-019-1883-8.
   PubMedGoogle Scholar
• Zhang T, Li Y, Zhu R, et al. Transcription factor p53 suppresses tumor growth by prompting pyroptosis in non-small-cell lung cancer. Oxid Med Cell Longev. 2019;2019:8746895. doi:10.1155/2019/8746895.
   PubMed Web of Science ®Google Scholar
• Man SM, Kanneganti TD. Regulation of inflammasome activation. Immunol Rev. 2015;265(1):6–21. doi:10.1111/imr.12296.
   PubMed Web of Science ®Google Scholar
• Shi J, Zhao Y, Wang K, et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature. 2015;526(7575):660–665. doi:10.1038/nature15514.
   PubMed Web of Science ®Google Scholar
• Zhang M, Jin C, Yang Y, et al. AIM2 promotes non-small-cell lung cancer cell growth through inflammasome-dependent pathway. J Cell Physiol. 2019;234(11):20161–20173. doi:10.1002/jcp.28617.
   PubMed Web of Science ®Google Scholar
• Yu Q, Zhang M, Ying Q, et al. Decrease of AIM2 mediated by luteolin contributes to non-small cell lung cancer treatment. Cell Death Dis. 2019;10:218. doi:10.1038/s41419-019-1447-y.
   PubMed Web of Science ®Google Scholar
• Sorrentino R, Terlizzi M, Di CrescenzoVG, et al. Human lung cancer-derived immunosuppressive plasmacytoid dendritic cells release IL-1α in an AIM2 inflammasome-dependent manner. Am J Pathol. 2015;185(11):3115–3124. doi:10.1016/j.ajpath.2015.07.009.
   PubMed Web of Science ®Google Scholar
• Qi M, Dai D, Liu J, et al. AIM2 promotes the development of non-small cell lung cancer by modulating mitochondrial dynamics. Oncogene. 2020;39(13):2707–2723. doi:10.1038/s41388-020-1176-9.
   PubMed Web of Science ®Google Scholar
• Poyet JL, Srinivasula SM, Tnani M, et al. Identification of Ipaf, a human caspase-1-activating protein related to Apaf-1. J Biol Chem. 2001;276(30):28309–28313. doi:10.1074/jbc.C100250200.
   PubMed Web of Science ®Google Scholar
• Yang J, Zhao Y, Shi J, Shao F. Human NAIP and mouse NAIP1 recognize bacterial type III secretion needle protein for inflammasome activation. Proc Natl Acad Sci USA. 2013;110(35):14408–14413. doi:10.1073/pnas.1306376110.
   PubMed Web of Science ®Google Scholar
• Canna SW, de Jesus AA, Gouni S, et al. An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nat Genet. 2014;46(10):1140–1146. doi:10.1038/ng.3089.
   PubMed Web of Science ®Google Scholar
• Romberg N, Al MoussawiK, Nelson-WilliamsC, et al. Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation. Nat Genet. 2014;46(10):1135–1139. doi:10.1038/ng.3066.
   PubMed Web of Science ®Google Scholar
• Allen IC, TeKippe EM, Woodford R-MT, et al. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J Exp Med. 2010;207(5):1045–1056. doi:10.1084/jem.20100050.
   PubMed Web of Science ®Google Scholar
• Hu B, Elinav E, Huber S, et al. Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. Proc Natl Acad Sci USA. 2010;107(50):21635–21640. doi:10.1073/pnas.1016814108.
   PubMed Web of Science ®Google Scholar
• Kolb R, et al. Obesity-associated NLRC4 inflammasome activation drives breast cancer progression. Nat Commun. 2016;7:13007. doi:10.1038/ncomms13007.
   PubMed Web of Science ®Google Scholar
• Tschopp J, Martinon F, Burns K. NALPs: A novel protein family involved in inflammation. Nat Rev Mol Cell Biol. 2003;4(2):95–104. doi:10.1038/nrm1019.
   PubMed Web of Science ®Google Scholar
• Huang T, Yin H, Ning W, et al. Expression of inflammasomes NLRP1, NLRP3 and AIM2 in different pathologic classification of lupus nephritis. Clin Exp Rheumatol. 2020;38(4):680–690.
   PubMed Web of Science ®Google Scholar
• Modlin IM, Kidd M, Latich I, et al. Genetic differentiation of appendiceal tumor malignancy: a guide for the perplexed. Ann. Surg. 2006;244(1):52–60. doi:10.1097/01.sla.0000217617.06782.d5.
   PubMed Web of Science ®Google Scholar
• Dieudé P, Guedj M, Wipff J, et al. NLRP1 influences the systemic sclerosis phenotype: a new clue for the contribution of innate immunity in systemic sclerosis-related fibrosing alveolitis pathogenesis. Ann Rheum Dis. 2011;70(4):668–674. doi:10.1136/ard.2010.131243.
   PubMed Web of Science ®Google Scholar
• Girardelli M, et al. NLRP1 polymorphisms in patients with asbestos-associated mesothelioma. Infect Agent Cancer. 2012;7(1):25. doi:10.1186/1750-9378-7-25.
   PubMedGoogle Scholar
• Zhai Z, Liu W, Kaur M, et al. NLRP1 promotes tumor growth by enhancing inflammasome activation and suppressing apoptosis in metastatic melanoma. Oncogene. 2017;36(27):3820–3830. doi:10.1038/onc.2017.26.
   PubMed Web of Science ®Google Scholar
• Richards N, Schaner P, Diaz A, et al. Interaction between pyrin and the apoptotic speck protein (ASC) modulates ASC-induced apoptosis. J Biol Chem. 2001;276(42):39320–39329. doi:10.1074/jbc.M104730200.
   PubMed Web of Science ®Google Scholar
• Chae JJ, Wood G, Masters SL, et al. The B30.2 domain of pyrin, the familial mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci USA. 2006;103(26):9982–9987. doi:10.1073/pnas.0602081103.
   PubMed Web of Science ®Google Scholar
• Bernot A, et al. A candidate gene for familial Mediterranean fever. Nat. Genet. 1997;17:25–31. doi:10.1038/ng0997-25.
   PubMed Web of Science ®Google Scholar
• Masters SL, Lagou V, Jéru I, et al. Familial autoinflammation with neutrophilic dermatosis reveals a regulatory mechanism of pyrin activation. Sci Transl Med. 2016;8(332):332ra45. doi:10.1126/scitranslmed.aaf1471.
   PubMed Web of Science ®Google Scholar
• Sharma D, Malik A, Guy CS, et al. Pyrin inflammasome regulates tight junction integrity to restrict colitis and tumorigenesis. Gastroenterology. 2018;154(4):948–964.e8. doi:10.1053/j.gastro.2017.11.276.
   PubMed Web of Science ®Google Scholar
• Voronov E, Shouval DS, Krelin Y, et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA. 2003;100(5):2645–2650. doi:10.1073/pnas.0437939100.
   PubMed Web of Science ®Google Scholar
• Xu H, Ding Q, Jiang HW. Genetic polymorphism of interleukin-1A (IL-1A), IL-1B, and IL-1 receptor antagonist (IL-1RN) and prostate cancer risk. Asian Pac J Cancer Prev. 2014;15(20):8741–8747. doi:10.7314/apjcp.2014.15.20.8741.
   PubMedGoogle Scholar
• Nutter F, Holen I, Brown HK, et al. Different molecular profiles are associated with breast cancer cell homing compared with colonisation of bone: evidence using a novel bone-seeking cell line. Endocr Relat Cancer. 2014;21(2):327–341. doi:10.1530/ERC-13-0158.
   PubMed Web of Science ®Google Scholar
• Li Y, Wang L, Pappan L, Galliher-Beckley A, Shi J. IL-1β promotes stemness and invasiveness of colon cancer cells through Zeb1 activation. Mol Cancer. 2012;11:87 doi:10.1186/1476-4598-11-87.
   PubMed Web of Science ®Google Scholar
• Xiong D, Feng R, Yang S, Lin T, Chen X. Antitumor activity of interleukin-18 on A549 human lung cancer cell line. J Cancer Res Ther. 2019;15(7):1635–1641. doi:10.4103/jcrt.JCRT_226_19.
   PubMed Web of Science ®Google Scholar
• Li B, et al. Predictive value of IL-18 and IL-10 in the prognosis of patients with colorectal cancer. Oncol. Lett. 2019;18:713–719.
   PubMedGoogle Scholar
• Chatenoud L, Ferran C, Legendre C, et al. In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation. 1990;49(4):697–702. doi:10.1097/00007890-199004000-00009.
   PubMed Web of Science ®Google Scholar
• Chatenoud L, et al. Systemic reaction to the Anti–T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-α. New Eng J Med. 1989;320:1420–1421.
   PubMed Web of Science ®Google Scholar
• Shimabukuro-Vornhagen A, Gödel P, SubkleweM, et al. Cytokine release syndrome. J Immunother Cancer. 2018;6:56. doi:10.1186/s40425-018-0343-9.
   PubMed Web of Science ®Google Scholar
• Honjo O, et al. Severe cytokine release syndrome resulting in purpura fulminans despite successful response to nivolumab therapy in a patient with pleomorphic carcinoma of the lung: a case report. J Immunother Cancer. 2019;7:97.
   PubMed Web of Science ®Google Scholar
• Kogure Y, Ishii Y, OkiM. Cytokine release syndrome with pseudoprogression in a patient with advanced non-small cell lung cancer treated with pembrolizumab. J Thorac Oncol. 2019;14(3):e55–e57. doi:10.1016/j.jtho.2018.11.025.
   PubMed Web of Science ®Google Scholar
• Lee DW, Gardner R, PorterDL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188–195. doi:10.1182/blood-2014-05-552729.
   PubMed Web of Science ®Google Scholar
• Walle LV, et al. Negative regulation of the NLRP3 inflammasome by A20 protects against arthritis. Nature. 2014;512:69–73.
   PubMed Web of Science ®Google Scholar
• Lee J, RheeMH, KimE, ChoJY. BAY 11-7082 is a broad-spectrum inhibitor with anti-inflammatory activity against multiple targets. Mediators Inflamm. 2012;2012:416036. doi:10.1155/2012/416036.
   PubMed Web of Science ®Google Scholar
• Yang C-H, Yen T-L, Hsu C-Y, et al. Multi-targeting andrographolide, a novel NF-κB inhibitor, as a potential therapeutic agent for stroke. IJMS. 2017;18(8):1638. doi:10.3390/ijms18081638.
   Google Scholar
• Kim M-J, Bae G-S, Jo I-J, et al. Fraxinellone inhibits inflammatory cell infiltration during acute pancreatitis by suppressing inflammasome activation. Int Immunopharmacol. 2019;69:169–177. doi:10.1016/j.intimp.2019.01.043.
   PubMed Web of Science ®Google Scholar
• Huai W, et al. Aryl hydrocarbon receptor negatively regulates NLRP3 inflammasome activity by inhibiting NLRP3 transcription. Nat Commun. 2014;5:5738. doi:10.1038/ncomms5738.
   PubMed Web of Science ®Google Scholar
• Zhong Z, Umemura A, Sanchez-Lopez E, et al. NF-κB restricts inflammasome activation via elimination of damaged mitochondria. Cell. 2016;164(5):896–910. doi:10.1016/j.cell.2015.12.057.
   PubMed Web of Science ®Google Scholar
• Guarda G, Braun M, Staehli F, et al. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity. 2011;34(2):213–223. doi:10.1016/j.immuni.2011.02.006.
   PubMed Web of Science ®Google Scholar
• Gaikwad S, Patel D, Agrawal-Rajput R. CD40 negatively regulates ATP-TLR4-activated inflammasome in microglia. Cell Mol Neurobiol. 2017;37(2):351–359. doi:10.1007/s10571-016-0358-z.
   PubMed Web of Science ®Google Scholar
• Perregaux D, et al. IL-1β maturation: evidence that mature cytokine formation can be induced specifically by nigericin. J. Immunol. 1992;149:1294–1303.
   PubMed Web of Science ®Google Scholar
• Yu JW, Lee MS. Mitochondria and the NLRP3 inflammasome: physiological and pathological relevance. Arch Pharm Res. 2016;39(11):1503–1518. doi:10.1007/s12272-016-0827-4.
   PubMed Web of Science ®Google Scholar
• Hornung V, Bauernfeind F, Halle A, et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol. 2008;9(8):847–856. doi:10.1038/ni.1631.
   PubMed Web of Science ®Google Scholar
• Caicedo MS, Samelko L, McAllister K, Jacobs JJ, Hallab NJ. Increasing both CoCrMo-alloy particle size and surface irregularity induces increased macrophage inflammasome activation in vitro potentially through lysosomal destabilization mechanisms. J Orthop Res. 2013;31(10):1633–1642. doi:10.1002/jor.22411.
   PubMed Web of Science ®Google Scholar
• Coll RC, Hill JR, Day CJ, et al. MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition. Nat Chem Biol. 2019;15(6):556–559. doi:10.1038/s41589-019-0277-7.
   PubMed Web of Science ®Google Scholar
• Chen L, Huang C-F, Li Y-C, et al. Blockage of the NLRP3 inflammasome by MCC950 improves anti-tumor immune responses in head and neck squamous cell carcinoma. Cell Mol Life Sci. 2018;75(11):2045–2058. doi:10.1007/s00018-017-2720-9.
   PubMed Web of Science ®Google Scholar
• He H, et al. Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity. Nat. Commun. 2018;9(1):2550. doi:10.1038/s41467-018-04947-6.
   PubMed Web of Science ®Google Scholar
• Jiang H, He H, ChenY, et al. Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders. J Exp Med. 2017;214(11):3219–3238. doi:10.1084/jem.20171419.
   PubMed Web of Science ®Google Scholar
• Wannamaker W, Davies R, NamchukM, et al. (S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1beta and IL-18. J Pharmacol Exp Ther. 2007;321(2):509–516. doi:10.1124/jpet.106.111344.
   PubMed Web of Science ®Google Scholar
• Randle JCR, Harding MW, Ku G, Schönharting M, Kurrle R. ICE/Caspase-1 inhibitors as novel anti-inflammatory drugs. Expert Opin Investig Drugs. 2001;10(7):1207–1209. doi:10.1517/13543784.10.7.1207.
   PubMed Web of Science ®Google Scholar
• Thornberry NA, Rano TA, Peterson EP, et al. A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. J Biol Chem. 1997;272(29):17907–17911. doi:10.1074/jbc.272.29.17907.
   PubMed Web of Science ®Google Scholar
• Greaney AJ, Maier NK, Leppla SH, Moayeri M. Sulforaphane inhibits multiple inflammasomes through an Nrf2-independent mechanism. J Leukoc Biol. 2016;99(1):189–199. doi:10.1189/jlb.3A0415-155RR.
   PubMed Web of Science ®Google Scholar
• Cocco M, Pellegrini C, Martínez-Banaclocha H, et al. Development of an acrylate derivative targeting the NLRP3 inflammasome for the treatment of inflammatory bowel disease. J Med Chem. 2017;60(9):3656–3671. doi:10.1021/acs.jmedchem.6b01624.
   PubMed Web of Science ®Google Scholar
• Youm Y-H, Nguyen KY, Grant RW, et al. The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med. 2015;21(3):263–269. doi:10.1038/nm.3804.
   PubMed Web of Science ®Google Scholar
• Juliana C, Fernandes-Alnemri T, Wu J, et al. Anti-inflammatory compounds parthenolide and bay 11-7082 are direct inhibitors of the inflammasome. J Biol Chem. 2010;285(13):9792–9802. doi:10.1074/jbc.M109.082305.
   PubMed Web of Science ®Google Scholar
• Honda H, Nagai Y, Matsunaga T, et al. Isoliquiritigenin is a potent inhibitor of NLRP3 inflammasome activation and diet-induced adipose tissue inflammation. J Leukoc Biol. 2014;96(6):1087–1100. doi:10.1189/jlb.3A0114-005RR.
   PubMed Web of Science ®Google Scholar
• Canakinumab Anti-Inflammatory Thrombosis Outcomes Study - American College of Cardiology. https://www.acc.org/latest-in-cardiology/clinical-trials/2017/08/26/08/35/cantos. Accessed November 29, 2020.
   Google Scholar
• Kernel Networks Inc. This study will evaluate the effect of canakinumab or pembrolizumab given as monotherapy or in combination as neo-adjuvant treatment for subjects with early stages NSCLC. CMR. 2019. doi:10.31525/ct1-nct03968419.
   Google Scholar
• Sasaki CT, Doukas SG, Vageli DP. In vivo short-term topical application of BAY 11-7082 prevents the acidic bile-induced mRNA and miRNA oncogenic phenotypes in exposed murine hypopharyngeal mucosa. Neoplasia. 2018;20(4):374–386. doi:10.1016/j.neo.2018.02.001.
   PubMed Web of Science ®Google Scholar
• Evaluate the efficacy and safety of andrographolide sulfonate in patients with acute bronchitis. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03132623?term= Andrographolide&cond=INFECTION& draw=2&rank=4. Accessed November 29, 2020.
   Google Scholar
• Hou L, Liu Q, Shen L, et al. Nano-delivery of fraxinellone remodels tumor microenvironment and facilitates therapeutic vaccination in desmoplastic melanoma. Theranostics. 2018;8(14):3781–3796. doi:10.7150/thno.24821.
   PubMed Web of Science ®Google Scholar
• Rudolphi K, Gerwin N, Verzijl N, van der Kraan P, van den BergW. Pralnacasan, an inhibitor of interleukin-1β converting enzyme, reduces joint damage in two murine models of osteoarthritis. Osteoarthr Cartil. 2003;11(10):738–746. doi:10.1016/S1063-4584(03)00153-5.
   PubMed Web of Science ®Google Scholar
• Boost KA, Hoegl S, Hofstetter C, et al. Targeting caspase-1 by inhalation-therapy: effects of Ac-YVAD-CHO on IL-1β, IL-18 and downstream proinflammatory parameters as detected in rat endotoxaemia. Intens Care Med. 2007;33(5):863–871. doi:10.1007/s00134-007-0588-0.
   PubMed Web of Science ®Google Scholar
• Ahn H, Kwon HM, Lee E, et al. Role of inflammasome regulation on immune modulators. J Biomed Res. 2018;32(5):401–410. doi:10.7555/JBR.32.20170120.
   PubMedGoogle Scholar
• Tang D, Liu H, Zhao Y, et al. Genetic variants of BIRC3 and NRG1 in the NLRP3 inflammasome pathway are associated with non-small cell lung cancer survival. Am J Cancer Res. 2020;10(8):2582–2595.
   PubMed Web of Science ®Google Scholar
• Hammad DR, Elgazzar AG, Essawy TS, Abd El SameieSA. Evaluation of serum interleukin-1 beta as an inflammatory marker in COPD patients. Egypt J Chest Dis Tuberc. 2015;64(2):347–352. doi:10.1016/j.ejcdt.2015.01.005.
   Web of Science ®Google Scholar